Click for next page ( 66


The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 65
7 Additional Challenges A few additional challenges were mentioned by workshop partici- pants but not dwelled on to a large extent. In addition to medicine-based approaches, a major effort in applying nanotechnology to cancer preven- tion is to use nanomaterials in food packaging to improve food storage so cancer-preventing nutrients in food stay fresher, according to Dr. Hawk. Cookware may also be coated with a “nanoglaze” to prevent toxic by- products of cooking from surfacing onto foods. Industry is also pursuing the development of nano-based food supplements, Dr. Hawk said. As mentioned earlier, others mentioned the need to explain the difference between risks related to nanomaterials in food or in the environment as compared to nanomedicine. Dr. Barker noted the need for patient privacy protections with per- sonalized nanomedicines, and the major challenge of having clinicians adopt nanotechnologies, once they are on the market. “The biggest barrier we have is convincing our colleagues to use these new interventions, to displace what they know how to do with something that they don’t quite understand,” she said. Reluctance to adopt nanomedicine has delayed its clinical testing, she added, noting the significant challenge of finding clinicians willing to run clinical trials of nanomedicines. Dr. Li noted the challenge of acquiring sufficient financial funding to develop nanotechnologies and bring them into the clinic. He started a small company to fund the development of a nanomedicine, and although he raised 17 million dollars from private investors that kept him in busi- ness for two and half years, once the “dotcom bubble burst,” he said it 65

OCR for page 65
66 NANOTECHNOLOGY AND ONCOLOGY was difficult to sustain funding. But according to Dr. Barker, nanotechnol- ogy is an area of huge investment internationally, especially by venture capital firms. “It is very exciting to all of us to see this level of interest in terms of the financing world, which will make things happen,” she said. In regards to developing nanomedicines that can prevent cancer, Dr. Hawk claimed that there are major concerns by industry that such a venture will not be profitable because of the long time frames needed to conduct the relevant clinical studies, and because they may not be able to patent their discoveries.